Madeleine covers PCR, nucleic acid amplification, and sample prep technologies for GenomeWeb.
The company was founded earlier this year based on an improved method for multiple displacement amplification and a single-cell-variant caller.
The test was approved for lab use, but it runs on a platform with the potential for point-of-care applications.
The Dutch firm expects its product to be the first commercial test on the market to diagnose IBD by analyzing a patient's gut microbiome.
The technology has been a core capability of the firm, which is expanding its suite of products to address the broader needs of genomics researchers.
The Bay Area firm is planning to launch a low-cost, microfluidics-based infectious disease diagnostic called the Simple Chip in the next few years.
The method uses graphene-coated silica particles fused to complementary RNA to register impedance changes in the presence of viruses.
The company has also developed software that will enable automated melt curve analysis on Cepheid's existing GeneXpert platforms.
The firm's treatments are based on stimulating the innate immune system with drugs made from inactivated bacteria to restore normal immune function.
The company's "chip-in-a-tube" digital PCR system combines the advantages of droplet- and chip-based systems into a single platform.
The method uses chitosan-coated magnetic beads and bead-based lysis to reduce the number of sample prep steps.
Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.
An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.
At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.
In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.